Merck Announces that Chirfi Guindo will Lead Marketing for Merck Human Health
June 21 2022 - 4:10PM
Business Wire
Merck (NYSE: MRK), known as MSD outside the United States and
Canada, today announced that Chirfi Guindo will lead Human Health
Marketing as chief marketing officer for Merck Human Health, and
will join Merck’s Executive Team, effective July 1, 2022. Guindo
will report directly to Robert M. Davis, chief executive officer
and president, Merck. As previously announced, Jannie
Oosthuizen leads Merck Human Health U.S., and Joe
Romanelli will lead Merck Human Health International effective
Aug. 1, both also reporting to Davis. Deepak Khanna, interim leader
of Human Health International, will retire at the end of this
year.
“Chirfi is a purpose-driven leader, dedicated to saving and
improving lives around the world. He has deep experience and a
proven track record in strategy, marketing and commercialization
across primary care, specialty care and rare diseases, in both
developed and developing markets,” said Mr. Davis. “I am confident
that our Human Health leaders, along with our entire Executive
Team, will build on the strong momentum of our business as we
deliver value to all our stakeholders, continue to address some of
the most pressing medical challenges and make a positive and
lasting impact on global health.”
As chief marketing officer for Human Health, Guindo will be
responsible for leading the development and implementation of the
company’s long-term strategy for the Human Health portfolio
spanning oncology, vaccines, pharmaceutical and pipeline
products.
Since 2017, Guindo has been executive vice president and head of
global product strategy and commercialization at Biogen and served
on Biogen’s executive leadership team. In this role, Guindo led
global strategy, marketing and commercialization for Biogen’s
neurology business. He also led the late-stage Product Development
and Commercialization Teams, and oversaw corporate strategy and
alliances, value and access, communications, policy, advocacy and
corporate responsibility.
Before joining Biogen, Guindo began his Merck career in 1990 and
spent more than 25 years in finance, sales, commercial and
marketing roles of increasing responsibility in the U.S. and
globally. He led global marketing for Merck’s HIV portfolio, and
also led Merck’s Human Health businesses in Canada, the Netherlands
and South Africa. Guindo has been recognized for developing strong
talent and forging innovative public-private partnerships and
elevating the profile of Merck as a patient-focused company. A
graduate of Ecole Centrale de Paris with a degree in engineering,
he also holds a Master of Business Administration from New York
University’s Stern School of Management.
About Merck At Merck, known as MSD outside of the United
States and Canada, we are unified around our purpose: We use the
power of leading-edge science to save and improve lives around the
world. For more than 130 years, we have brought hope to humanity
through the development of important medicines and vaccines. We
aspire to be the premier research-intensive biopharmaceutical
company in the world – and today, we are at the forefront of
research to deliver innovative health solutions that advance the
prevention and treatment of diseases in people and animals. We
foster a diverse and inclusive global workforce and operate
responsibly every day to enable a safe, sustainable and healthy
future for all people and communities. For more information, visit
www.merck.com and connect with us on Twitter, Facebook, Instagram,
YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway,
N.J., USA This news release of Merck & Co., Inc.,
Kenilworth, N.J., USA (the “company”) includes “forward-looking
statements” within the meaning of the safe harbor provisions of the
U.S. Private Securities Litigation Reform Act of 1995. These
statements are based upon the current beliefs and expectations of
the company’s management and are subject to significant risks and
uncertainties. If underlying assumptions prove inaccurate or risks
or uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of the global outbreak of novel coronavirus disease
(COVID-19); the impact of pharmaceutical industry regulation and
health care legislation in the United States and internationally;
global trends toward health care cost containment; technological
advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining
regulatory approval; the company’s ability to accurately predict
future market conditions; manufacturing difficulties or delays;
financial instability of international economies and sovereign
risk; dependence on the effectiveness of the company’s patents and
other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s Annual
Report on Form 10-K for the year ended December 31, 2021 and the
company’s other filings with the Securities and Exchange Commission
(SEC) available at the SEC’s Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220621006093/en/
Media Contacts: Johanna Herrmann (617) 216-6019
Investor Contacts: Peter Dannenbaum (908) 740-1037
Damini Chokshi (908) 740-1807
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024